Puma Biotechnology, Inc. (NASDAQ:PBYI) Insider Jeffrey Jerome Ludwig Sells 9,437 Shares

Puma Biotechnology, Inc. (NASDAQ:PBYI) insider Jeffrey Jerome Ludwig sold 9,437 shares of the company’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $3.15, for a total transaction of $29,726.55. Following the completion of the transaction, the insider now owns 108,951 shares of the company’s stock, valued at approximately $343,195.65. This trade represents a 7.97 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink.

Puma Biotechnology Stock Down 5.4 %

PBYI stock opened at $2.95 on Monday. Puma Biotechnology, Inc. has a 52 week low of $2.22 and a 52 week high of $7.73. The company has a quick ratio of 1.40, a current ratio of 1.42 and a debt-to-equity ratio of 0.46. The firm has a 50-day simple moving average of $2.99 and a 200-day simple moving average of $2.97. The stock has a market capitalization of $144.81 million, a P/E ratio of 6.15 and a beta of 1.10.

Puma Biotechnology (NASDAQ:PBYI) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, beating analysts’ consensus estimates of $0.31 by $0.10. The business had revenue of $80.50 million during the quarter, compared to analysts’ expectations of $71.32 million. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. During the same quarter in the prior year, the firm earned $0.12 earnings per share. Equities analysts forecast that Puma Biotechnology, Inc. will post 0.31 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Puma Biotechnology

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Rice Hall James & Associates LLC lifted its stake in shares of Puma Biotechnology by 3.3% in the second quarter. Rice Hall James & Associates LLC now owns 144,792 shares of the biopharmaceutical company’s stock worth $472,000 after buying an additional 4,686 shares in the last quarter. Patriot Financial Group Insurance Agency LLC lifted its stake in Puma Biotechnology by 72.7% in the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 19,000 shares of the biopharmaceutical company’s stock worth $48,000 after purchasing an additional 8,000 shares in the last quarter. Royce & Associates LP boosted its holdings in shares of Puma Biotechnology by 71.8% during the 3rd quarter. Royce & Associates LP now owns 20,165 shares of the biopharmaceutical company’s stock worth $51,000 after purchasing an additional 8,427 shares during the last quarter. Squarepoint Ops LLC grew its position in shares of Puma Biotechnology by 17.7% in the second quarter. Squarepoint Ops LLC now owns 71,391 shares of the biopharmaceutical company’s stock valued at $233,000 after purchasing an additional 10,757 shares in the last quarter. Finally, SG Americas Securities LLC acquired a new stake in shares of Puma Biotechnology in the third quarter valued at approximately $34,000. Institutional investors and hedge funds own 61.29% of the company’s stock.

Wall Street Analyst Weigh In

PBYI has been the subject of a number of analyst reports. StockNews.com cut Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Friday, December 6th. HC Wainwright reiterated a “buy” rating and set a $7.00 target price on shares of Puma Biotechnology in a research report on Monday, December 23rd.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.